Whittier Trust Co. grew its stake in shares of Allergan plc (NYSE:AGN) by 0.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 53,319 shares of the company’s stock after acquiring an additional 267 shares during the period. Whittier Trust Co.’s holdings in Allergan were worth $8,973,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the company. Liberty Wealth Management LLC raised its stake in Allergan by 35.3% in the second quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock worth $43,000 after buying an additional 67 shares in the last quarter. TRUE Private Wealth Advisors raised its stake in Allergan by 4.5% in the third quarter. TRUE Private Wealth Advisors now owns 1,715 shares of the company’s stock worth $288,000 after buying an additional 74 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its stake in Allergan by 43.1% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 259 shares of the company’s stock worth $44,000 after buying an additional 78 shares in the last quarter. Moody National Bank Trust Division raised its stake in Allergan by 0.4% in the third quarter. Moody National Bank Trust Division now owns 24,411 shares of the company’s stock worth $4,108,000 after buying an additional 93 shares in the last quarter. Finally, Reilly Financial Advisors LLC raised its stake in Allergan by 129.3% in the third quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock worth $29,000 after buying an additional 97 shares in the last quarter. 80.52% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have issued reports on AGN shares. Sanford C. Bernstein lowered shares of Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price target on the stock. in a report on Tuesday, July 16th. Mizuho lowered shares of Allergan from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $171.00 to $188.00 in a report on Wednesday, June 26th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $184.00 price target (up from $176.00) on shares of Allergan in a report on Monday, September 30th. SunTrust Banks lifted their price target on shares of Allergan to $185.00 and gave the stock a “buy” rating in a report on Wednesday, July 3rd. Finally, UBS Group lifted their price target on shares of Allergan from $172.00 to $189.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $179.15.
Shares of AGN traded up $1.10 during trading hours on Friday, reaching $173.60. 2,582,900 shares of the company traded hands, compared to its average volume of 2,180,941. The stock has a market capitalization of $56.60 billion, a P/E ratio of 10.40, a P/E/G ratio of 2.04 and a beta of 1.65. The company has a quick ratio of 0.91, a current ratio of 1.03 and a debt-to-equity ratio of 0.34. Allergan plc has a 12-month low of $114.27 and a 12-month high of $191.72. The business has a fifty day moving average price of $166.16 and a 200-day moving average price of $152.51.
Allergan (NYSE:AGN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $4.34 by $0.04. The firm had revenue of $4.09 billion for the quarter, compared to analyst estimates of $3.93 billion. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the company earned $4.42 earnings per share. As a group, research analysts predict that Allergan plc will post 16.68 EPS for the current fiscal year.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: How to Invest in a Bull Market
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.